Manufacturing

AI Citation Gap in CDMO Capacity: Pharmaceutical Manufacturing Examples and Insights

This article examines the AI citation gap in CDMO capacity for pharmaceutical manufacturing, providing concrete examples and strategic insights. It clarifies the CDMO industry, compares CDMO vs CRO, and highlights top CDMO pharma companies.

Manufacturing pipeline approvals: what the evidence confirms

This plan covers what a manufacturing pipeline means, what EWIB does, and what the Eastern CT Manufacturing Pipeline Initiative publicly confirms. It stays tightly grounded in the available evidence and avoids unsupported outlook claims.

Optimizing Pharmaceutical Manufacturing: The Critical Role of Dew Point Monitoring

This whitepaper highlights the critical importance of dew point monitoring in industrial applications, particularly for ensuring product quality and equipment integrity in pharmaceutical manufacturing.

FDA Declines Cingulate's ADHD Drug CTx-1301 Over Manufacturing Concerns

The U.S. Food and Drug Administration (FDA) has declined to approve Cingulate's attention deficit hyperactivity disorder (ADHD) treatment, CTx-1301, due to manufacturing-related concerns. While the drug's safety and effectiveness were not questioned, the Complete Response Letter (CRL) signifies a delay in the company's market entry.

FDA Approves 17 Drugs with Continuous Manufacturing: Implications for Pharma

The FDA has approved 17 drugs using continuous manufacturing, signaling a shift in production technology. This growth in emerging tech has significant implications for the pharmaceutical industry.

Pharma Manufacturing World 2026: Key Insights and Expectations

As Pharma Manufacturing World 2026 approaches, key insights and expectations are emerging. This article previews the event's agenda, key players, and potential catalysts.

Bristol Myers' $1B Manufacturing Plant Plans in Houston

Bristol Myers is considering a significant investment in a $1B manufacturing plant in Houston, which could reshape its operational landscape. This article delves into the implications for the pharmaceutical sector.

Biologics and Manufacturing Challenges in Biopharma

As biologics take the lead in biopharma pipelines, manufacturing challenges are hindering new product launches. This article explores the implications for the industry.